ResearcherUniversity of California, Los AngelesActive in the last 2 years
Caius Gabriel Radu
Matched on ORCID iD 0000-0002-9338-5397; OpenAlex author ID A5018755772; NIH RePORTER profile ID 6922113. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 1)
- Trials
- 0
- Grants
- 5
- Labs led
- 1
- Collaborators
- 29
2017: 1 paper · 2018: 1 grant · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper, 2 grants · 2026: 1 paper, 2 grants
Papers 9
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
- Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Co-author DOI 10.1073/pnas.2517786122↗
- MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling. Co-author DOI 10.1158/1078-0432.ccr-22-3322↗
- Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1066↗
- Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Last author DOI 10.1016/j.celrep.2021.110236↗
- Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0623↗
- NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Co-author DOI 10.1073/pnas.2012469118↗
- Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Co-author DOI 10.1073/pnas.1812410116↗
- Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Co-author DOI 10.18632/oncotarget.13572↗
Grants 5
- Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors R01CA283736↗
- Causes and Consequences of Adenosine Signaling in Pancreatic Cancer R01CA290888↗
- Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer R01CA250529↗
- Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer R01CA260678↗
- PET Imaging-guided Personalized Therapy in Pancreatic Cancer R01CA187678↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy R. Donahue · 8 shared papers, 4 shared grants, 2017–2026 · strength 4.17
- Zev A. Wainberg · 1 shared paper, 2 shared grants, 2025–2026 · strength 2.06
- Grant Causes and Consequences of Adenosine Signaling in Pancreatic Cancer R01CA290888↗
- Grant Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer R01CA260678↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Norbert Pardi · 1 shared grant, 2026 · strength 1.26
- Evan R. Abt · 5 shared papers, 2019–2026 · strength 0.64
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- David W. Dawson · 5 shared papers, 2017–2026 · strength 0.63
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer. DOI 10.1158/1535-7163.mct-21-0623↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Jason M. Link · 3 shared papers, 2022–2026 · strength 0.47
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Johannes Czernin · 1 shared paper, 1 shared grant, 2018–2022 · strength 0.39
- Razmik Ghukasyan · 4 shared papers, 2017–2023 · strength 0.38
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Paper Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. DOI 10.1073/pnas.1812410116↗
- Keke Liang · 3 shared papers, 2021–2023 · strength 0.36
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Lili Yang · 1 shared paper, 2025 · strength 0.26
- Yan-Ruide Li · 1 shared paper, 2025 · strength 0.26
- Irmina A. Elliott · 3 shared papers, 2017–2021 · strength 0.23
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Paper Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. DOI 10.1073/pnas.1812410116↗
- Paper Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. DOI 10.18632/oncotarget.13572↗
- Jing Cui · 2 shared papers, 2021–2022 · strength 0.21
- Mark D. Girgis · 1 shared paper, 2026 · strength 0.21
- Shineui Kim · 1 shared paper, 2026 · strength 0.21
- Michael K. Srienc · 1 shared paper, 2026 · strength 0.21
- Jonathan C. King · 1 shared paper, 2026 · strength 0.21
- Oscar Joe Hines · 1 shared paper, 2026 · strength 0.21
- Alexandra M. Moore · 2 shared papers, 2019–2021 · strength 0.17
- Joon Y. Park · 1 shared paper, 2023 · strength 0.15
- Kristina Y. Aguilera · 1 shared paper, 2022 · strength 0.15
- Salina Yuan · 1 shared paper, 2023 · strength 0.13
- Samantha B. Kemp · 1 shared paper, 2023 · strength 0.13
- Benjamin Kahn · 1 shared paper, 2023 · strength 0.13
- Noah C. Cheng · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.